| pubmed-article:21570434 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0024518 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0006611 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:21570434 | lifeskim:mentions | umls-concept:C0301521 | lld:lifeskim |
| pubmed-article:21570434 | pubmed:issue | 29-30 | lld:pubmed |
| pubmed-article:21570434 | pubmed:dateCreated | 2011-6-13 | lld:pubmed |
| pubmed-article:21570434 | pubmed:abstractText | An optimal cancer vaccine should be able to induce highly potent, long-lasting, tumor-specific responses in the majority of the cancer patient population. One approach for achieving this is to use synthetic peptide vaccines derived from widely expressed tumor-associated antigens, that promiscuously bind multiple MHC class I and class II alleles. MUC1-SP-L (ImMucin, VXL100) is a 21mer peptide encoding the complete signal peptide domain of MUC1, a tumor-associated antigen expressed by over 90% of solid and non-solid tumors. MUC1-SP-L was predicted in silico to bind various MHC class I and MHC class II alleles, covering the majority of the Caucasian population. PBLs obtained from 13 naïve donors all proliferated, with a Stimulation Index (SI?2), to the MUC1-SP-L peptide, producing mixed CD4+ and CD8+ responses. Similar results were manifested by MUC1-SP-L in PBLs derived from 9 of 10 cancer patients with MUC1 positive tumors. CD4+ and CD8+ T cell populations exhibited CD45RO memory markers and secreted IFN-gamma and IL-2 following stimulation with MUC1-SP-L. These T cells also exhibited proliferation to the MUC1-SP-L inner 9mer epitopes and cytotoxicity against tumor cell lines expressing MUC1 and a concordant MHC class I allele. Cytotoxicity to MUC1-expressing human and murine tumors was shown also in T cells obtained from HLA-A2 transgenic mice and BALB/c syngeneic mice immunized with the MUC1-SP-L and GM-CSF. In an immunotherapy model, BALB/c mice inoculated with metastatic MUC1 transfected murine DA3 mammary tumor cells, exhibited significantly prolonged survival following vaccination with MUC1-SP-L. Our results indicate superior immunological and anti-tumor properties of MUC1-SP-L compared to previously published MUC1-derived epitopes. | lld:pubmed |
| pubmed-article:21570434 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21570434 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21570434 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21570434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21570434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21570434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21570434 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21570434 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21570434 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21570434 | pubmed:issn | 1873-2518 | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:SmorodinskyNe... | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:LiuStellaS | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:BrennerBaruch... | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:RosenbaumEliE | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:CarmonLiorL | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:KovjazinRivaR | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:KundelYuliaY | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:HornGalitG | lld:pubmed |
| pubmed-article:21570434 | pubmed:author | pubmed-author:MedaliaGalG | lld:pubmed |
| pubmed-article:21570434 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21570434 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21570434 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:21570434 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:21570434 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21570434 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21570434 | pubmed:pagination | 4676-86 | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:meshHeading | pubmed-meshheading:21570434... | lld:pubmed |
| pubmed-article:21570434 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21570434 | pubmed:articleTitle | ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. | lld:pubmed |
| pubmed-article:21570434 | pubmed:affiliation | Vaxil BioTherapeutics Ltd., 13 Einstein Street, Weizmann Science Park, Nes-Ziona 74036, Israel. | lld:pubmed |
| pubmed-article:21570434 | pubmed:publicationType | Journal Article | lld:pubmed |
